GlassScriptPhysician profile
Akber M Safi
NPI 1215264189
$9,231.71
in general payments reported to CMS, 2019-2025
50 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $1,043 · 2021: $1,592 · 2022: $1,588 · 2023: $1,165 · 2024: $1,440 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,629.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.64 | 2019-2025 | Ubrelvy, Vraylar, Dalvance |
| Glaxosmithkline, LLC. | $1,103.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $795.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $691.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $541.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $411.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $359.13 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $346.25 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Astellas Pharma US INC | $319.12 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $260.63 | 2019-2023 | |
| Amarin Pharma, INC. | $257.56 | 2019-2022 | |
| Amgen INC. | $239.96 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $197.62 | 2022-2024 | |
| Seqirus USA INC | $179.72 | 2021-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Allergan, INC. | $163.60 | 2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akber Safi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.